Nu-Med Plus raises $450,000 in preferred stock sale amid mining pivot
What's the deal? Nu-Med PlusDealroom has a profile for this one. Try Dealroom → has raised $450,000 by selling 171,232 shares of Series A Preferred Stock to two accredited investors, according to a Form 8-K filed October 20, 2026. The sale, priced at $2.628 per share, closed a day earlier on October 19.
The fine print: The preferred shares convert into common stock on a 20-for-one basis, meaning the investor stake could become 3,424,640 common shares. Separately, Nu-Med issued 50,000 preferred shares to a consultant for services rendered — convertible into another 1,000,000 common shares. No sales commissions were paid.
Why it matters: The raise sits in the bottom tier of disclosed funding rounds by size, ranking in roughly the 4th percentile. It is modest cash for a small company — but it fits a broader pattern of equity issuance.
The bigger picture: Nu-Med recently acquired gold explorer Avid Gold and agreed to buy six Canadian mineral properties, using preferred shares rather than cash. The new financing adds fresh capital to fund that expansion into mining.
What could go wrong? The heavy reliance on convertible preferred stock creates dilution risk for common shareholders, and the company carries outstanding obligations tied to the Avid Gold deal. The conversion ratio is not adjusted for any future reverse stock split.
The signal: For a small issuer short on cash, preferred equity has become the currency of choice — paying for acquisitions, services, and now operations alike. The $450,000 raise matters less as a financing event than as evidence of how Nu-Med is funding its pivot: one share issuance at a time.
Read more: kalkine.com
